Close Menu

NEW YORK – Singapore-based genomic medicine startup Lucence Diagnostics plans to enter the US cancer market by building a laboratory in Silicon Valley and subsequently launching its LiquidHallmark late-stage lung cancer treatment selection next-generation sequencing assay in the second half of 2020.

The firm also presented the results of a validation study earlier this month, applying the error-correction sequencing amplicon-based platform in hematological cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.